An agile and highlycustomizable toolbox for drug discovery
How it works
1.
A humanized tumor xenograft is created from fluorescent labeled patient-derived cell lines (CDX) or patient-derived xenograft (PDX) material in zebrafish larvae.
2.
The tumor microenvironment can be customized by co-implantation of stroma or immune cells to analyze cell-cell communication in the tumor.
3.
Tumor-bearing zebrafish larvae are treated with the lead drug candidates, such as small molecules, large molecules, antibodies, ADCs, or therapeutic cells, for three days. Treatments can be added to the water or injected.
4.
Output shows efficacy of treatment-induced tumor regression and inhibition of metastasis invasion.
Our unique ZTX™ platform shortening time for drug discovery by providing in-vivo data on tumor regression and metastasis inhibition of compounds within 5 days
Explore Ztx™ Oncoleads
Our Output
Tumor efficacy
Fluorescent-labeled human cells can be visualized and followed over time in the transparent embryo.
Tumor size is measured in the living embryo by fluorescent microscopy, assessing the tumor-killing capacity of the compounds being tested.
Embryos are housed individually, and every embryo is tracked separately throughout the experiment.
Metastasis invation
The fast development of the embryo enables rapid vascularization and invasion of the developed microtumor.
Metastatic cells will disseminate from the primary site into the vasculature and to the hematopoietic site in the embryo´s tail, where the metastatic cells will migrate to the tissue.
The analysis includes the potential of the compounds being tested to inhibit both local and distal metastatic dissemination.
